Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

By D. Calvisi, S. Ladu, Alexis Gorden, M. Farina, E. Conner, Ju-Seog Lee, V. Factor, Snorri Thorgeirsson. Gastroenterology, 2006

726 citations recorded by the source corpus.

Subfields: Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/220535c2cb40a58e49cda5dc0acd25f4a43e1ac7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. Riccardo Lencioni
4. V. Mazzaferro
5. Andrew X. Zhu
6. Peter R. Galle
7. T. de Baère
8. T. Greten

In Oncology

1. Jordi Bruix1 , 2
2. Guobin He
3. V. Mazzaferro
4. M. Karin
5. J. Llovet
6. J. Avruch
7. N. Bardeesy
8. N. Perkins

Citations in the corpus

• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “%) present with abnormal AFP serum levels, a fact that has been recently correlated with a molecular subclass of aggressive HCCs (S2 class, EpCAM positive) [77–79].”
• Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression (2010, background): “A survey of different signaling molecules in human HCC revealed frequent activation of ERK and STAT3, especially in HCCs with poor prognosis, as well as reduced p38 activation, relative to the surrounding liver tissue (Calvisi et al., 2006).”
• Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging (2011, background): “Signaling via the Ras/Raf/MEK/ERK cascade plays a critical role in liver carcinogenesis [86-91].”
• Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling (2008, background): “Signaling through the Raf/ MEK/ERK cascade, as well as angiogenesis, are reported to have important roles in the development of HCC (66).”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “%) present with abnormal AFP serum levels, a fact that has been recently correlated with a molecular subclass of aggressive HCCs (S2 class, EpCAM positive) [77–79].”
• Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. (2014, background): “It was observed that honokiol induced the expression of SHP-1 protein in HepG2 cells in a dose-dependent manner, with maximum expression at 25–50 μM [29].”
• Mst1 and Mst2 maintain hepatocyte quiescence and suppress the development of hepatocellular carcinoma through inactivation of the Yap1 oncogene (2009, positive): “of human tumors including HCC (Calvisi et al., 2006; Donninger et al., 2007; Macheiner et al., 2009) it is plausible that their diminished expression might result in defective regulation of MST1/2 signaling.”